BIRC3 is altered in 4.23% of marginal zone lymphoma patients [3].

Chlorambucil and rituximab have evidence of efficacy in patients with BIRC3 mutation in marginal zone lymphoma [4].

Chlorambucil and rituximab have evidence of efficacy in patients with BIRC3 mutation in mature B-cell lymphoma/leukemia [4].

BIRC3 is altered in 1.99% of cervical carcinoma patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is altered in 3.52% of head and neck squamous cell carcinoma patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is altered in 1.84% of diffuse large B-cell lymphoma patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is altered in 2.48% of lymphoma patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is altered in 2.02% of peripheral T-cell lymphoma, not otherwise specified patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is altered in 1.06% of cancer patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is altered in 0.58% of multiple myeloma patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is altered in 0.21% of acute myeloid leukemia patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is altered in 0.17% of myelodysplastic syndromes patients [3].

BIRC3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for enteropathy-associated T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for hepatosplenic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and hepatosplenic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for monomorphic epitheliotropic intestinal T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and monomorphic epitheliotropic intestinal T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for sezary syndrome, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and sezary syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BIRC3 is an inclusion criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].